Skip to main content
Top
Gepubliceerd in:

28-02-2018

Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China

Auteurs: Liu Liu, Shunping Li, Yue Zhao, Jianglin Zhang, Gang Chen

Gepubliceerd in: Quality of Life Research | Uitgave 5/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To investigate the validity of direct and indirect health state utility (HSU) and subjective well-being measures in psoriasis vulgaris patients.

Methods

A convenience sampling framework was used to successively recruit patients with psoriasis vulgaris from the outpatient clinics of a tertiary hospital in Changsha, Central South China. Participants completed time trade-off (TTO), standard gamble (SG), the five-level EQ-5D (EQ-5D-5L), the WHO-5 well-being index, and the psoriasis disability index (PDI). The concurrent and known-groups validity of HSUs and well-being index in psoriasis patients were firstly studied. The agreements among HSUs and the relationship between HSU and well-being measures were further explored.

Results

A valid sample of 343 patients was analyzed. Mean HSU and well-being scores elicited from the EQ-5D-5L/TTO/SG and WHO-5 were 0.90/0.85/0.88 and 13.69, respectively. The Spearman correlation (concurrent validity) was the strongest between PDI and WHO-5 (r = 0.45), followed by with EQ-5D-5L (0.38), SG (r = 0.20), and the TTO (r = 0.18). The pairwise intraclass correlation coefficients among the three HSU measures were < 0.30. The known-groups validity was evident in all measures except for the SG. Exploratory factor analysis further suggests a complementary relationship between the EQ-5D-5L and WHO-5.

Conclusions

There is a poor agreement between direct and indirect methods on measuring HSU with psoriasis vulgaris. Results from this study recommend that the EQ-5D-5L is the most preferred method to elicit HSU from psoriasis vulgaris patients in mainland China. It is important to further analyze the subjective well-being in addition to the HSU to fully understand the impact of psoriasis.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Parisi, R., Symmons, D. P., Griffiths, C. E., & Ashcroft, D. M., (2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377–385.CrossRefPubMed Parisi, R., Symmons, D. P., Griffiths, C. E., & Ashcroft, D. M., (2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377–385.CrossRefPubMed
2.
go back to reference Ding, X., Wang, T., Shen, Y., Wang, X., Zhou, C., Tian, S., et al. (2012). Prevalence of psoriasis in China: A population-based study in six cities. European Journal of Dermatology, 22(5), 663–667.PubMed Ding, X., Wang, T., Shen, Y., Wang, X., Zhou, C., Tian, S., et al. (2012). Prevalence of psoriasis in China: A population-based study in six cities. European Journal of Dermatology, 22(5), 663–667.PubMed
3.
go back to reference Shao, C. G., Zhang, G. W., & Wang, G. C. (1987). Distribution of psoriasis in China: A nationwide screening. Proceedings of the Chinese Academy of Medical Sciences Peking Union Medical College, 2(2), 59–65. Shao, C. G., Zhang, G. W., & Wang, G. C. (1987). Distribution of psoriasis in China: A nationwide screening. Proceedings of the Chinese Academy of Medical Sciences Peking Union Medical College, 2(2), 59–65.
4.
go back to reference Palfreeman, A. C., McNamee, K. E., & McCann, F. E. (2013). New developments in the management of psoriasis and psoriatic arthritis: A focus on apremilast. Drug Design, Development and Therapy, 7, 201–210.CrossRefPubMedCentralPubMed Palfreeman, A. C., McNamee, K. E., & McCann, F. E. (2013). New developments in the management of psoriasis and psoriatic arthritis: A focus on apremilast. Drug Design, Development and Therapy, 7, 201–210.CrossRefPubMedCentralPubMed
5.
go back to reference Colombo, D., & Perego, R. (2013). Quality of life in psoriasis. In H. Lima (Ed.), Psoriasis: types, causes and medication (Chap. 07). Rijeka: InTech. Colombo, D., & Perego, R. (2013). Quality of life in psoriasis. In H. Lima (Ed.), Psoriasis: types, causes and medication (Chap. 07). Rijeka: InTech.
7.
go back to reference Brazier, J., Ratcliffe, J., Salomon, J., & Tsuchiya, A. (2016). Measuring and valuing health benefits for economic evaluation (2nd edn). Oxford: Oxford University Press.CrossRef Brazier, J., Ratcliffe, J., Salomon, J., & Tsuchiya, A. (2016). Measuring and valuing health benefits for economic evaluation (2nd edn). Oxford: Oxford University Press.CrossRef
8.
go back to reference Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5(1), 1–30.CrossRefPubMed Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5(1), 1–30.CrossRefPubMed
9.
go back to reference von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behavior. Princeton: Princeton University Press. von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behavior. Princeton: Princeton University Press.
10.
go back to reference Torrance, G. W., Thomas, W. H., & Sackett, D. L. (1972). A utility maximization model for evaluation of health care programs. Health Services Research, 7(2), 118–133.PubMedCentralPubMed Torrance, G. W., Thomas, W. H., & Sackett, D. L. (1972). A utility maximization model for evaluation of health care programs. Health Services Research, 7(2), 118–133.PubMedCentralPubMed
11.
go back to reference Attema, A. E., Edelaar-Peeters, Y., Versteegh, M. M., & Stolk, E. A. (2013). Time trade-off: One methodology, different methods. European Journal of Health Economics, 14(Suppl 1), S53–S64.CrossRefPubMed Attema, A. E., Edelaar-Peeters, Y., Versteegh, M. M., & Stolk, E. A. (2013). Time trade-off: One methodology, different methods. European Journal of Health Economics, 14(Suppl 1), S53–S64.CrossRefPubMed
12.
go back to reference Gray, A. M., Clarke, P. M., Wolstenholme, J. L., & Wordsworth, S. (2010). Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press. Gray, A. M., Clarke, P. M., Wolstenholme, J. L., & Wordsworth, S. (2010). Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press.
14.
go back to reference Richardson, J., Mckie, J., & Bariola, E. (2014). Multiattribute utility instruments and their use. Encyclopedia of Health Economics, 2, 341–357.CrossRef Richardson, J., Mckie, J., & Bariola, E. (2014). Multiattribute utility instruments and their use. Encyclopedia of Health Economics, 2, 341–357.CrossRef
15.
go back to reference Arnold, D., Girling, A., Stevens, A., & Lilford, R. (2009). Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis. BMJ, 339, b2688.CrossRefPubMedCentralPubMed Arnold, D., Girling, A., Stevens, A., & Lilford, R. (2009). Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis. BMJ, 339, b2688.CrossRefPubMedCentralPubMed
16.
go back to reference Cubi-Molla, P., de Vries, J., & Devlin, N. (2014). A study of the relationship between health and subjective well-being in Parkinson’s disease patients. Value in Health, 17(4), 372–379.CrossRefPubMed Cubi-Molla, P., de Vries, J., & Devlin, N. (2014). A study of the relationship between health and subjective well-being in Parkinson’s disease patients. Value in Health, 17(4), 372–379.CrossRefPubMed
18.
go back to reference Luo, N., Li, M., Liu, G. G., Lloyd, A., de Charro, F., & Herdman, M. (2013). Developing the Chinese version of the new 5-level EQ-5D descriptive system: The response scaling approach. Quality of Life Research, 22(4), 885–890.CrossRefPubMed Luo, N., Li, M., Liu, G. G., Lloyd, A., de Charro, F., & Herdman, M. (2013). Developing the Chinese version of the new 5-level EQ-5D descriptive system: The response scaling approach. Quality of Life Research, 22(4), 885–890.CrossRefPubMed
19.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedCentralPubMed Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedCentralPubMed
20.
go back to reference Luo, N., Liu, G., Li, M., Guan, H., Jin, X., & Rand-Hendriksen, K. (2017). Estimating an EQ-5D-5L value set for China. Value in Health, 20(4), 662–669.CrossRefPubMed Luo, N., Liu, G., Li, M., Guan, H., Jin, X., & Rand-Hendriksen, K. (2017). Estimating an EQ-5D-5L value set for China. Value in Health, 20(4), 662–669.CrossRefPubMed
21.
go back to reference Topp, C. W., Ostergaard, S. D., Sondergaard, S., & Bech, P. (2015). The WHO-5 Well-Being Index: A systematic review of the literature. Psychotherapy and Psychosomatics, 84(3), 167–176.CrossRefPubMed Topp, C. W., Ostergaard, S. D., Sondergaard, S., & Bech, P. (2015). The WHO-5 Well-Being Index: A systematic review of the literature. Psychotherapy and Psychosomatics, 84(3), 167–176.CrossRefPubMed
22.
go back to reference Bech, P., Gudex, C., & Johansen, K. S. (1996). The WHO (Ten) well-being index: Validation in diabetes. Psychotherapy & Psychosomatics, 65(4), 183–190.CrossRef Bech, P., Gudex, C., & Johansen, K. S. (1996). The WHO (Ten) well-being index: Validation in diabetes. Psychotherapy & Psychosomatics, 65(4), 183–190.CrossRef
23.
go back to reference Finlay, A. Y., & Kelly, S. E. (1987). Psoriasis: An index of disability. Clinical & Experimental Dermatology, 12(1), 8–11.CrossRef Finlay, A. Y., & Kelly, S. E. (1987). Psoriasis: An index of disability. Clinical & Experimental Dermatology, 12(1), 8–11.CrossRef
24.
go back to reference Finlay, A. Y., & Coles, E. C. (1995). The effect of severe psoriasis on the quality of life of 369 patients. British Journal of Dermatology, 132(2), 236–244.CrossRefPubMed Finlay, A. Y., & Coles, E. C. (1995). The effect of severe psoriasis on the quality of life of 369 patients. British Journal of Dermatology, 132(2), 236–244.CrossRefPubMed
25.
go back to reference He, Z., Lu, C., Ou, A., Fang, J., Wang, D., Deng, J., et al. (2012). Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis. Health & Quality of Life Outcomes, 10, 37.CrossRef He, Z., Lu, C., Ou, A., Fang, J., Wang, D., Deng, J., et al. (2012). Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis. Health & Quality of Life Outcomes, 10, 37.CrossRef
26.
go back to reference Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis–oral therapy with a new retinoid. Dermatologica, 157(4), 238–244.CrossRefPubMed Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis–oral therapy with a new retinoid. Dermatologica, 157(4), 238–244.CrossRefPubMed
27.
go back to reference Schmitt, J., & Wozel, G. (2005). The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology, 210(3), 194–199.CrossRefPubMed Schmitt, J., & Wozel, G. (2005). The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology, 210(3), 194–199.CrossRefPubMed
28.
go back to reference Fayers, P., & Machin, D. (2013). Quality of life: The assessment, analysis and interpretation of patient-reported outcomes: Wiley. Fayers, P., & Machin, D. (2013). Quality of life: The assessment, analysis and interpretation of patient-reported outcomes: Wiley.
29.
go back to reference Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1(8476), 307–310.CrossRefPubMed Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1(8476), 307–310.CrossRefPubMed
30.
go back to reference Zhou, Z., Fang, Y., Zhou, Z., Li, D., Wang, D., Li, Y., et al. (2017). Assessing income-related health inequality and horizontal inequity in China. Social Indicators Research, 132(1), 241–256.CrossRef Zhou, Z., Fang, Y., Zhou, Z., Li, D., Wang, D., Li, Y., et al. (2017). Assessing income-related health inequality and horizontal inequity in China. Social Indicators Research, 132(1), 241–256.CrossRef
31.
go back to reference Poor, A. K., Rencz, F., Brodszky, V., Gulacsi, L., Beretzky, Z., Hidvegi, B., et al. (2017). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 26(12), 3409–3419.CrossRefPubMed Poor, A. K., Rencz, F., Brodszky, V., Gulacsi, L., Beretzky, Z., Hidvegi, B., et al. (2017). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 26(12), 3409–3419.CrossRefPubMed
32.
go back to reference Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.CrossRefPubMed Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.CrossRefPubMed
33.
go back to reference Lundberg, L., Johannesson, M., Silverdahl, M., Hermansson, C., & Lindberg, M. (1999). Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology, 141(6), 1067–1075.CrossRefPubMed Lundberg, L., Johannesson, M., Silverdahl, M., Hermansson, C., & Lindberg, M. (1999). Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology, 141(6), 1067–1075.CrossRefPubMed
34.
go back to reference Boye, K. S., Matza, L. S., Feeny, D. H., Johnston, J. A., Bowman, L., & Jordan, J. B. (2014). Challenges to time trade-off utility assessment methods: When should you consider alternative approaches? Expert Review of Pharmacoeconomics & Outcomes Research, 14(3), 437–450.CrossRef Boye, K. S., Matza, L. S., Feeny, D. H., Johnston, J. A., Bowman, L., & Jordan, J. B. (2014). Challenges to time trade-off utility assessment methods: When should you consider alternative approaches? Expert Review of Pharmacoeconomics & Outcomes Research, 14(3), 437–450.CrossRef
35.
go back to reference Matza, L. S., Boye, K. S., Feeny, D. H., Bowman, L., Johnston, J. A., Stewart, K. D., et al. (2015). The time horizon matters: Results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. European Journal of Health Economics Hepac Health Economics in Prevention & Care, 17(8), 1–12. Matza, L. S., Boye, K. S., Feeny, D. H., Bowman, L., Johnston, J. A., Stewart, K. D., et al. (2015). The time horizon matters: Results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. European Journal of Health Economics Hepac Health Economics in Prevention & Care, 17(8), 1–12.
36.
go back to reference Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2017). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22.CrossRefPubMed Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2017). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22.CrossRefPubMed
37.
go back to reference Gamst-Klaussen, T., Chen, G., Lamu, A. N., & Olsen, J. A. (2016). Health state utility instruments compared: Inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D. Quality of Life Research, 25(7), 1667–1678.CrossRefPubMed Gamst-Klaussen, T., Chen, G., Lamu, A. N., & Olsen, J. A. (2016). Health state utility instruments compared: Inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D. Quality of Life Research, 25(7), 1667–1678.CrossRefPubMed
38.
go back to reference Wang, Y., Tan, N. C., Tay, E. G., Thumboo, J., & Luo, N. (2015). Cross-cultural measurement equivalence of the 5-level EQ-5D (EQ-5D-5L) in patients with type 2 diabetes mellitus in Singapore. Health & Quality of Life Outcomes, 13(1), 103.CrossRef Wang, Y., Tan, N. C., Tay, E. G., Thumboo, J., & Luo, N. (2015). Cross-cultural measurement equivalence of the 5-level EQ-5D (EQ-5D-5L) in patients with type 2 diabetes mellitus in Singapore. Health & Quality of Life Outcomes, 13(1), 103.CrossRef
39.
go back to reference Clemens, S., Begum, N., Harper, C., Whitty, J. A., & Scuffham, P. A. (2014). A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Quality of Life Research, 23(8), 2375–2381.CrossRefPubMed Clemens, S., Begum, N., Harper, C., Whitty, J. A., & Scuffham, P. A. (2014). A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Quality of Life Research, 23(8), 2375–2381.CrossRefPubMed
Metagegevens
Titel
Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China
Auteurs
Liu Liu
Shunping Li
Yue Zhao
Jianglin Zhang
Gang Chen
Publicatiedatum
28-02-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1819-2